MedPath

Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers

Phase 2
Completed
Conditions
Hematologic Neoplasms
Bone Marrow Neoplasms
Non-Hodgkin's Lymphoma
Interventions
Registration Number
NCT00421213
Lead Sponsor
Alaunos Therapeutics
Brief Summary

The study of safety of a new organic arsenic compound in the treatment of hematological malignancies.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Single ArmDarinaparsin-
Primary Outcome Measures
NameTimeMethod
Response Rate6 months
Secondary Outcome Measures
NameTimeMethod
toxicities6 months
© Copyright 2025. All Rights Reserved by MedPath